caldya®


Adapting at the Speed of Science

From Pre-IND through Post Marketing Surveillance



Tailored Solutions Along the Clinical Trial Pathway

Unique medical challenges call for tailored and adaptable solutions. We're aligned with the rapid change inherent to biopharma innovators and equipped to help you navigate the drug development process. And we think a little differently here at Caidya. We listen to clients – prioritizing your goals as we partner together to bring life-changing new therapies to the global community.



Patient Centric Solutions

Our culture and structure empower our teams to build personalized, patient-centric solutions that deliver studies efficiently and effectively. An ownership mentality – including access to executive leadership – and the expertise and willingness to be flexible produce the agility required to navigate complex clinical trials at the speed of your innovation. Side by side with you, we ensure your projects meet today's needs, while preparing for tomorrow's demands. That's why companies that work with Caidya stay with Caidya.

Corporate Experience: Last 5 Years



Complementing our corporate track record is the individual therapeutic proficiency of our operations teams. For example, therapeutic experience across our project management team members includes: 95%+ in oncology, 70%+ in rare disease and pediatrics, 66%+ in cardiovascular, and significant experience in several other fast-growing areas, like hematology, dermatology and ophthalmology.

Where We Operate

Our distinct global reach and tailored approaches help you conduct successful regional or multi-regional studies utilizing efficient operational models, local in-market expertise, and harmonized technologies, enabling better healthcare outcomes for all.

TO REALIZE OUR MISSION, THE GLOBAL POPULATION MUST BE ACCESSIBLE FOR STUDIES — THAT'S WHY YOU'LL FIND US CONDUCTING STUDIES IN EVERY KEY REGION



Governance, Sustainability, Regulatory and Compliance

- Governance: While a privately held company, we follow best practices for corporate governance, including having Independent Directors and Board committees. Our investor base is formed by best-in-class global private equity, venture capital and healthcare specialist investors.
- Global, inclusive workforce: We have employees in 25 countries/regions with 72% of all employees, 67% of managerial positions and 54% of executive leadership positions held by women (including CEO).
- Al Principles: Caidya is committed to the responsible and ethical use of Artificial Intelligence (Al) in our operations, prioritizing patient well-being, ensuring legal and regulatory compliance and maintaining the integrity of the clinical study process.
- Quality Management: Our globally harmonized Quality Management System (QMS) combined with systematic staff training and QA oversight results in minimal to no audit findings from sponsor and government regulatory auditors.

Regulatory Compliance: Having conducted studies in 50+ countries/regions over the past 5 years, Caidya has a global program ensuring compliance with all applicable laws and regulations. This includes a comprehensive data privacy/security program to ensure compliance with data collection, processing and transfer under applicable laws and regulations, including EU GDPR, China PIPL, and US state and federal laws.

Corporate Structure: Caidya is the trade name of dMedClinical Co. Ltd. (Cayman Islands) and its global holdings. Clinipace, Inc. is one company in the Caidya group of companies. In 2021, Clinipace, Inc. was acquired by dMedClinical Co. Ltd., a privately held company, whose investors include entities located in the People's Republic of China (PRC), and which may be subject to PRC laws and regulations that differ from those of the United States.

caidya.com